focus -WSS

focus

author：hotspot 2025-09-28 02:32:19 - browse：1433

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Obamacare plans could cover weight loss drugs

WSS

Hospitals are piloting generative AI tools as regulators play catch

Illinois Supreme Court finds assault weapons ban constitutional

Idaho college killings prosecutors challenge defense's grand jury claims

Congress may force more Covid

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Bird flu researchers hone in on Finland’s mink farms

focus

focus

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Illumina slashes 2023 revenue projections yet again

Wildfire smoke exposes gaps in outdoor worker protections

Patients, digital health players weigh in on FTC's data privacy plan

Supreme Court strikes down use of affirmative action

Illumina slashes 2023 revenue projections yet again

Walensky prepares to leave CDC — and Congress — behind

Idaho college killings prosecutors challenge defense's grand jury claims

ChatGPT in medicine: STAT answers readers' burning questions

Mark Cuban is blaming the wrong people for high drug costs

focus

Illumina slashes 2023 revenue projections yet again

Reporting on presidential health from Reagan to Trump and Biden

Obamacare plans could cover weight loss drugs

Surprise medical billing ban raises prices elsewhere

Bird flu researchers hone in on Finland’s mink farms

Researchers tackle phage therapy hurdles for wider adoption

Wikipedia

focus

leisure time

leisure time